Search clinical trials for: BMS-986337

Total 3154 results

Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd; Nektar Therapeutics

Completed

An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors

Advanced Cancer

Japan
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Withdrawn

Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer

Resectable Biliary Tract Cancer
Celgene

Recruiting

An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma (KarMMa-2)

Multiple Myeloma

United States, France, Germany, Spain, United Kingdom, Italy
Bristol-Myers Squibb

Active, not recruiting

A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy (MERCUTIO)

Cardiomyopathy, Hypertrophic

Italy, United States, Poland, Spain
Nektar Therapeutics
Bristol-Myers Squibb

Terminated

Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)

Melanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III

United States, Spain, Germany, France, Australia, Italy, Greece, Israel, Russian Federation, New Zealand, Austria, United Kingdom, Netherlands, Portugal, Poland, Czechia, Romania
Bristol-Myers Squibb

Recruiting

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

Melanoma | Carcinoma, Renal Cell | Cervical Cancer | Pancreatic Adenocarcinoma | Ovarian Neoplasms | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Neoplasms | Urothelial Carcinoma | Microsatellite Stable Colorectal Cancer | Non-Small-Cell Lung Cancer | Gastric/Gastroesophageal Junction...

United States, Australia, Italy, Germany, Spain, Canada, Israel, Japan
Bristol-Myers Squibb
Nektar Therapeutics

Completed

A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer

Bladder Cancer | Bladder Tumor | Muscle-Invasive Bladder Cancer

Russian Federation, China, Germany, Italy, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, France, Greece, Israel, Mexico, Netherlands, Poland, Spain, United Kingdom
Bristol-Myers Squibb

Recruiting

ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions (ELEMENT-MDS)

Myelodysplastic Syndromes

Canada, United States, China, Australia, France, Greece, Hungary, Germany, Italy, Czechia, Poland, Mexico, Spain, Brazil, Colombia, India, Argentina, Puerto Rico
Bristol-Myers Squibb
Cardioxyl Pharmaceuticals, Inc

Completed

A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure

Heart Failure

United States
H. Lee Moffitt Cancer Center and Research Institute
Secura Bio, Inc.

Active, not recruiting

Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy

Hodgkin Lymphoma | Non Hodgkin Lymphoma | Myeloma | Lymphocytic Leukemia

United States
Celgene

Not yet recruiting

Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants

Healthy Participants

United States
Celgene

Withdrawn

A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (ALUMMINATE)

Multiple Myeloma

China, Australia, United States, Argentina, Austria, Belgium, Brazil, Canada, Chile, Czechia, France, Germany, Greece, Hungary, India, Ireland, Italy, Japan, Korea, Republic of, Norway, Portugal, Romania, Spain, Sweden, Switzerland, Turkey, United Kingdom
Bristol-Myers Squibb

Active, not recruiting

A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States, France, Australia, Canada, Italy, Norway, Spain, Sweden, United Kingdom
Nektar Therapeutics
ImaginAb, Inc.

Withdrawn

A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab

Metastatic Melanoma

United States
Bristol-Myers Squibb

Completed

A Study to Assess the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb
Cardioxyl Pharmaceuticals, Inc

Completed

A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure

Heart Failure | Decompensated Heart Failure | Acute Heart Failure

United States, Germany, Jordan, Poland, Russian Federation
Bristol-Myers Squibb

Completed

To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding in Lung Using PET (Positron Emission Tomography) In Healthy Volunteers

Immunology

United States
Bristol-Myers Squibb

Recruiting

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission

Acute Myeloid Leukemia

Japan, United States
Bristol-Myers Squibb

Active, not recruiting

Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors

Advanced Solid Tumor

Canada, United States, Mexico
Bristol-Myers Squibb

Completed

An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers

Advanced Solid Cancers

United States, Canada
Celgene

Completed

A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.

Multiple Myeloma

Belgium, United Kingdom, Italy, Germany, Sweden, Denmark, Norway, Spain
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy

Crohn Disease

United States, Belgium, Hungary, France, Canada, Spain, Australia, Germany, Poland, United Kingdom
Celgene

Recruiting

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Lymphoma, Non-Hodgkin

United States, Korea, Republic of, China, Canada, France, Spain, Denmark, Brazil, Italy, Argentina, Chile, Israel, United Kingdom, Belgium, Austria
Compugen Ltd
Bristol-Myers Squibb

Active, not recruiting

COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.

Head and Neck Cancer | Ovarian Cancer | Solid Tumor | Endometrial Neoplasms

United States
Celgene

Active, not recruiting

A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders

Neoplasms | Hematologic Malignancies | Hematologic Neoplasm

United Kingdom, United States
Bristol-Myers Squibb

Recruiting

An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice

Colitis, Ulcerative

United States, United Kingdom
Bristol-Myers Squibb

Active, not recruiting

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

Argentina, Canada, France, Germany, Italy, Korea, Republic of, Poland, United States, Australia, China, Czechia, Denmark, Greece, Hong Kong, Japan, Spain, Sweden
Bristol-Myers Squibb

Completed

A Study to Evaluate Safety of Single Doses of BMS-986177 in Patients With End Stage Renal Disease (ESRD) Treated With Hemodialysis

Antithrombotic

United States
Bristol-Myers Squibb

Completed

A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy Subjects

Healthy Volunteers

United States
Juno Therapeutics, a Subsidiary of Celgene

Active, not recruiting

A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

United States
Bristol-Myers Squibb

Recruiting

A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors

Advanced Solid Tumors

Canada, United States, Argentina, France, Spain, Italy, Australia, Mexico, Chile
Janssen Research & Development, LLC
Bristol-Myers Squibb

Completed

A Study of JNJ-70033093 and Digoxin in Healthy Participants

Healthy

Belgium
Bristol-Myers Squibb

Completed

An Investigational Study of Continuous 8-Hour Intravenous Administrations of BMS-986231 in Participants With Heart Failure and Reduced Heart Function Given a Standard Dose of Loop Diuretic

Congestive Heart Failure | Heart Decompensation | Cardiac Failure | Myocardial Failure

United Kingdom
Janssen Pharmaceutica N.V., Belgium

Completed

A Study Evaluating Drug Drug Interaction Between Milvexian and Atorvastatin in Healthy Participants

Healthy

Belgium
Bristol-Myers Squibb

Recruiting

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

Canada, Taiwan, United States, Australia, Denmark, China, Korea, Republic of, Israel, Spain, France, Germany, Czechia, Austria, Japan, Sweden, United Kingdom, Greece, Italy, Finland, Argentina, Belgium, Brazil, Colombia, Hong Kong, India, Mexic... and more
Washington University School of Medicine
Bristol-Myers Squibb

Active, not recruiting

Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer

Triple Negative Breast Cancer

United States
China National Center for Cardiovascular Diseases
Peking University People's Hospital; Beijing Chao Yang Hospital; Hebei Medical...

Unknown

A New Classification and Interventional Therapy for Coronary Artery Ectasia (NCIPCAE)

Coronary Artery Ectasia

China
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

Progressive Pulmonary Fibrosis

China, United States, Taiwan, Japan, Korea, Republic of, Hungary, Canada, Argentina, Australia, Austria, Belgium, Brazil, Chile, Colombia, Denmark, Finland, France, Germany, Greece, India, Ireland, Italy, Mexico, Peru, Poland, Portugal, Spain, Switzerla... and more
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

China, Taiwan, United States, Australia, Japan, Korea, Republic of, United Kingdom, Canada, Israel, Argentina, Austria, Belgium, Brazil, Chile, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, India, Ireland, Italy, ... and more
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis

Multiple Sclerosis (MS)

United States, United Kingdom
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Efficacy and Long-term Safety of Oral Ozanimod in Chinese Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Ulcerative Colitis

China, Taiwan
Bristol-Myers Squibb

Recruiting

A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis

China
Bristol-Myers Squibb

Completed

A Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]BMS-986419 in Healthy Male Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Completed

A Multiple Dose Study to Assess the Safety and Tolerability of BMS-986166 in Healthy Volunteers

Ulcerative Colitis

United States
Bristol-Myers Squibb

Terminated

Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome

Sjögren's Syndrome

Australia, United States, Italy, Mexico, Colombia, Peru, Puerto Rico, South Africa, Chile, Poland, Russian Federation
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Drug Levels, Physical and Chemical Changes, and Removal of BMS-986196 in Healthy Male Participants

Healthy Male Volunteers

United States
Bristol-Myers Squibb

Completed

A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis

Pulmonary Fibrosis

Canada, France, United States, Argentina, Australia, Belgium, Brazil, Chile, China, Germany, Israel, Italy, Japan, Korea, Republic of, Mexico, Spain, Taiwan, United Kingdom
Bristol-Myers Squibb

Completed

A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus

Lupus Erythematosus, Cutaneous

Germany
Bristol-Myers Squibb

Terminated

Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid Tumors

Various Advanced Cancer

Australia, United States, Canada
Bristol-Myers Squibb

Completed

Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease

Alzheimer's Disease

France, Sweden, United States, Germany, Canada

Search clinical trials for: BMS-986337

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations